TB Alliance Appoints Jerome H. Kim, MD as next President and Chief Executive Officer

Dr. Mel Spigelman, current president and CEO of TB Alliance, and Dr. Jerome H. Kim, incoming president and CEO of TB Alliance

New CEO to begin in April 2027, leading TB Alliance’s next chapter in research, innovation, access, and impact

NEW YORK (November 17, 2026)—TB Alliance today announced that its Board of Directors has appointed Jerome H. Kim, MD as the organization’s next President and Chief Executive Officer, effective April 16, 2027. He will succeed Mel Spigelman, MD, who has led the organization since 2009.

Dr. Kim will continue to lead the International Vaccine Institute (IVI) as Director General until mid-April 2027. Dr. Spigelman will continue to serve as President and CEO of TB Alliance until Dr. Kim assumes his post, after which time Dr. Spigelman will continue to contribute his knowledge and insights to TB Alliance as a strategic advisor.

A recognized global health leader, Dr. Kim has served as Director General of IVI since 2015, where he has steered the organization’s multi-pronged global strategy and expansion to advance the development of an extensive portfolio of innovative vaccines. A hallmark of his leadership at IVI and throughout his career has been building strategic partnerships in the Asia-Pacific, Africa, Europe, and the Americas that span the intersection of government, science, academia, and the biotechnology industry to save lives and increase public health impact.

Dr. Kim is joining TB Alliance at a time when the organization, under Dr. Spigelman’s leadership, has transformed multidrug-resistant TB treatment through the groundbreaking success of the BPaL/M (bedaquiline, pretomanid, and linezolid with or without moxifloxacin) regimens, and is poised to achieve its next ambitious set of goals through its 1x1x1 strategy: a one-day treatment for latent TB infection, one-month treatment for active TB, and access to new treatments within one year of regulatory approval. Dr. Kim will provide strategic direction and executive leadership to accelerate the introduction of the next transformation in TB therapeutics through TB Alliance’s robust pipeline of novel drugs and regimens, research into long-acting injectable treatments, and partnerships with countries, manufacturers, and leading global health research and development (R&D) funders to accelerate the introduction of new treatments and scale up affordable, reliable access.

“I am honored to join TB Alliance and its world-class team, which has transformed what is possible in global TB treatment,” said Dr. Kim. “We have an opportunity to build on the tremendous progress TB Alliance has made under Mel Spigelman’s leadership to develop the next breakthroughs in TB innovation. I look forward to working with the TB Alliance Board, staff, partners, and patient communities to continue to expand affordable access to more effective treatments, and to accelerate the path to ending TB. I am grateful to IVI’s Board of Trustees and my colleagues, and I look forward to continuing our work together to ensure a seamless transition.”

Prior to IVI, Dr. Kim built an impressive record in translational medicine and clinical research in the US military medical system, where he assumed progressively more responsibility for HIV vaccine research and molecular virology. An infectious disease specialist, he received his M.D. from the Yale University School of Medicine and trained in Internal Medicine and Infectious Diseases at Duke University Medical Center. He is a Distinguished Visiting Professor in the College of Natural Sciences at Seoul National University, and he has received several prestigious awards, including the Medal of Honor for Civil Merit from the Government of the Republic of Korea and the Asia Pacific Vaccine Excellence Lifetime Achievement Award.

“Dr. Kim’s experience in leading a mission-centric organization focused on global health innovation will be invaluable as TB Alliance advances its research into long-acting injectables and other new technologies for simpler, faster delivery of TB treatments,” said David Norton, Chair of TB Alliance’s Board of Directors. “The Board is deeply grateful to Mel Spigelman for his strong leadership over nearly two decades and we look forward to partnering with Jerome Kim to build on TB Alliance’s remarkable record as the world’s leader in TB drug development.”

Under Dr. Spigelman’s leadership, TB Alliance has advanced new treatment options for people affected by TB, including the development of pretomanid and the six-month, all-oral BPaL/M regimens, which have helped transform treatment for drug-resistant TB. TB Alliance has also collaborated with partners to develop and introduce appropriately dosed, child-friendly TB medicines, making drug-sensitive TB treatment easier to administer to children around the world.

“It has been an extraordinary privilege to lead TB Alliance, and I am extremely proud of what our incredible team, partners, and funders have accomplished together over the past two decades,” said Dr. Spigelman. “Most of all, I am grateful to the millions of people around the world affected by TB, especially those who have volunteered to participate in TB clinical trials, without whose dedication, progress would never have been possible. They motivate us every day to find new treatments and to ensure those treatments are readily available and affordable to all in need. I look forward to passing the torch to Jerome Kim to lead the next era of impact for TB Alliance.”

About TB Alliance
TB Alliance is a not-for-profit organization dedicated to finding faster-acting and affordable drug regimens to fight TB. Through innovative science and with partners around the globe, we aim to ensure equitable access to faster, better TB cures that will advance global health and prosperity. TB Alliance operates with support from Australia’s Department of Foreign Affairs and Trade, Foreign, Commonwealth and Development Office (United Kingdom), Gates Foundation, Germany’s Federal Ministry of Research, Technology and Space (BMFTR) through KfW, Global Health Innovative Technology Fund, Raoul Follerau Foundation, United States Department of Defense Congressionally Directed Medical Research Programs (CDMRP), United States Department of State, United States National Institutes for Health – National Center for Advancing Translational Sciences (NCATS), and United States National Institutes for Health – National Institute of Allergy and Infectious Diseases (NIAID).

For more information, please visit: www.tballiance.org.

Media contact
Jess Wiggs
Jessica.Wiggs@tballiance.org
+1 646-616-8613